SCM
ALDX icon

Silverarc Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Silverarc Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-192,345
Closed -$2.18M – 84
2021
Q2 		$2.18M Sell
192,345
-129,534
-40% -$1.56M 0.97% 36
2021
Q1 		$3.82M Buy
+321,879
New +$3.71M 2.09% 15

Other funds holding ALDX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Silverarc Capital Management's ALDX Position: Q3 2021 in Review

Silverarc Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 192,345 shares — an estimated $2.18M sold.

Silverarc Capital Management first reported a position in ALDX in Q1 2021 and held it in 2 quarters. The position peaked at $3.82M in Q1 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

  • Silverarc Capital Management reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 192,345 Aldeyra Therapeutics shares in Q3 2021, an estimated $2.18M.
  • Silverarc Capital Management first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 2 quarters.
  • Silverarc Capital Management's Aldeyra Therapeutics position peaked at $3.82M in Q1 2021.
  • 117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.